Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eisai Co., Ltd.

32.19
+1.093.50%
Volume:411.00
Turnover:13.26K
Market Cap:9.07B
PE:45.47
High:32.19
Open:32.19
Low:32.19
Close:31.10
52wk High:44.65
52wk Low:22.51
Shares:281.89M
Float Shares:266.47M
Volume Ratio:0.86
T/O Rate:0.00%
Dividend:1.08
Dividend Rate:3.37%
EPS(TTM):0.7079
EPS(LYR):0.9775
ROE:5.85%
ROA:2.72%
PB:1.62
PE(LYR):32.93

Loading ...

Company Profile

Company Name:
Eisai Co., Ltd.
Exchange:
PINK LIMITED
Establishment Date:
1941
Employees:
10917
Office Location:
4-6-10, Koishikawa,Bunkyo-ku,Tokyo,Japan
Zip Code:
112-8088
Fax:
- -
Introduction:
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.